Generics of Complex Drugs Must Pass Korea FDA's Bioequivalence Test; Another Positive Development for MNCs
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea's Food and Drug Administration will soon require medicines made by Korean generic drug makers to pass the agency's bioequivalence test when producing copies of branded originals with more than two active ingredients, also known as complex drugs